Aquamer Medical Corporation (PINK: AQUM) is a development stage medical device company focused on the development and commercialization of injectable biocompatible products.
This afternoon, AQUM issued a quarterly report disclosing its receipt of an Investigational Device Exemption from the U.S. Food and Drug Administration and is undergoing pilot clinical evaluation. The AquaGen is being developed for the treatment of deep wrinkles, facial scars and various cosmetic plastic surgery procedures such as lip augmentation. Outcome from FDA can make this to see $1.00 easily. IMO.
The information is not intended as investment advice, as an on offer or solicitation of an offer to sell or buy. Subscribers and users of the free service assume the entire cost and risk of any trading they choose to undertake.